|
|
|
содержание .. 282 283 284 285 ..
СЕКЦИЯ 13 НАРУШЕНИЯ РИТМА СЕРДЦА 1140 ___________ 28. Hirsh J., Anand S.S., Halperin J.L. et al. (2001) Guide to Anticoagulant Ther- apy: Heparin. A Statement for Healthcare professionals From the American 29. Hirsh J., Fuster V., Ansell J. et al. (2003) American Heart Association/American Col- lege of Cardiology Foundation Guide to Warfarin Therapy. Circulation: 1692–1711. 30. Klein A.L., Grimm R.A., Murray R.D. et al. (2001) Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesopha- 31. Mark D., Cowper P., Bercowitz S. et al. (1998) Economic assessment of low- molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute 32. Nacarelli G.V., Dell’Orfano J.T., Wolbrette D.L. et al. (2000) Cost-effective management of acute atrial fi brillation: role of rate control, spontaneous con- 33. Ostermayer S.H., Reisman M., Kramer P.H. et al. (2005) Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in 34. Page R.L. (2000) Atrial Fibrillation takes the spotlight in the Arrhythmia Ses- sions at this year’s AHA. Annual Scientifi c Sessions of the American Heart 35. Reiter M., Bucek R.A., Koca N. et al. (2003) PERSIST. Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul. Fibrinol., 14(1): 61–65. 36. Roij er A., Eskilsson J., Olsson B. (2000) Transesophageal echocardiography- guided cardioversion atrial fi brillation and fl utter. Eur. Heart J., 21: 837–847. 37. Sievert H., Lech M., Treples T. et al. (2002) Percutaneous left atrial appendage transcatheter occlucion to prevent stroke high risk patients with atrial fi brilla- 38. Stellbrink D., Hanrath P. (2000) Optimal management cardio version atrial fi - brillation and fl utter: still a stunning problem. Eur. Heart J., 21: 793–798. 39. Stellbrink D., Nixdorff U., Hofmann T. et al. (2004) ACE (Anticoagulation in Car- dioversion using Enoxaparin) Study Group. Safety and effi cacy of enoxaparin 40. Stroke Prevention in Atrial Fibrillation Investigators: Transesophageal echocar- diographic correlates of thromboembolism in high- risk patients with nonvalvular 41. Thibault B., Talajic M., Dubuc M. et al. (2000) Thromboembolic events occur in patients with atrial fi brillation despite maintenance of sinus rhythm or use of 42. Turpie A.G., Gallus A.S., Hoek J.A. for the Pentasaccharide Investigators (2001) A synthetic pentasaccharide for the prevention of deep-vein thrombosis 42. Van Gelder I.C., Hagens V.E., Bosker H.A. (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fi brillation. New |